Literature DB >> 23751837

Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT.

David Taïeb1, Pablo Ureña-Torres, Paolo Zanotti-Fregonara, Domenico Rubello, Alice Ferretti, Ioline Henter, Jean-François Henry, Francesca Schiavi, Giuseppe Opocher, Johan G Blickman, Patrick M Colletti, Elif Hindié.   

Abstract

Secondary hyperparathyroidism (sHPT) is a major complication for patients with end-stage renal disease on long-term hemodialysis or peritoneal dialysis. When the disease is resistant to medical treatment, patients with severe sHPT are typically referred for parathyroidectomy (PTx), which usually improves biological parameters as well as clinical signs and symptoms. Unfortunately, early surgical failure with persistent disease may occur in 5%-10% of patients and recurrence reaches 20%-30% at 5 years. Presently, the use of parathyroid scintigraphy in sHPT is usually limited to the management of surgical failures after initial PTx. This review describes the strengths and limitations of typical (99m)Tc-sestamibi imaging protocols, and highlights the potential benefits of using parathyroid scintigraphy in the initial workup of surgical patients.

Entities:  

Mesh:

Year:  2013        PMID: 23751837      PMCID: PMC4300197          DOI: 10.1097/RLU.0b013e31829af5bf

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  40 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

Review 3.  The surgical management of renal hyperparathyroidism.

Authors:  Catherine Madorin; Randall P Owen; William D Fraser; Phillip K Pellitteri; Brian Radbill; Alessandra Rinaldo; Raja R Seethala; Ashok R Shaha; Carl E Silver; Matthew Y Suh; Barrie Weinstein; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-20       Impact factor: 2.503

4.  Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism.

Authors:  Sophie Périé; Hafedh Fessi; Marc Tassart; Nassima Younsi; Isabelle Poli; Jean Lacau St Guily; Jean-Noël Talbot
Journal:  Am J Kidney Dis       Date:  2005-02       Impact factor: 8.860

5.  Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy.

Authors:  David Fuster; Juan Ybarra; Jaime Ortin; José-Vicente Torregrosa; Rosa Gilabert; Xavier Setoain; Pilar Paredes; Joan Duch; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

6.  Usefulness of the combination of ultrasonography and 99mTc-sestamibi scintigraphy in the preoperative evaluation of uremic secondary hyperparathyroidism.

Authors:  Carlo Vulpio; Maurizio Bossola; Annamaria De Gaetano; Giulia Maresca; Isabella Bruno; Guido Fadda; Francesca Morassi; Sabina C Magalini; Alessandro Giordano; Marco Castagneto
Journal:  Head Neck       Date:  2010-09       Impact factor: 3.147

7.  Parathyroidectomy: whom and when?

Authors:  Rosa Jofré; Juan Manuel López Gómez; Javier Menárguez; José Ramón Polo; Martin Guinsburg; Teresa Villaverde; Isabel Pérez Flores; Diana Carretero; Patrocinio Rodríguez Benitez; Rafael Pérez García
Journal:  Kidney Int Suppl       Date:  2003-06       Impact factor: 10.545

8.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

9.  Comparison of five parathyroid scintigraphic protocols.

Authors:  Virpi Tunninen; Pekka Varjo; Jukka Schildt; Aapo Ahonen; Tomi Kauppinen; Irina Lisinen; Anu Holm; Hannu Eskola; Marko Seppänen
Journal:  Int J Mol Imaging       Date:  2013-01-21

10.  Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.

Authors:  Jürgen Floege; Joseph Kim; Elizabeth Ireland; Charles Chazot; Tilman Drueke; Angel de Francisco; Florian Kronenberg; Daniele Marcelli; Jutta Passlick-Deetjen; Guntram Schernthaner; Bruno Fouqueray; David C Wheeler
Journal:  Nephrol Dial Transplant       Date:  2010-04-25       Impact factor: 5.992

View more
  14 in total

1.  Clinical Utility of Tc-99m MIBI SPECT/CT for Preoperative Localization of Parathyroid Lesions.

Authors:  Zeynep Gozde Ozkan; Seher Nilgun Unal; Serkan Kuyumcu; Yasemin Sanli; Mehmet Fatih Gecer; Beyza Ozcinar; Yasemin Senyurek Giles; Yesim Erbil
Journal:  Indian J Surg       Date:  2016-05-04       Impact factor: 0.656

Review 2.  Pediatric hyperparathyroidism: review and imaging update.

Authors:  Hedieh Khalatbari; Safia H E Cheeney; Scott C Manning; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2021-04-27

3.  Use of [11C]choline PET/CT for visualization of four hyperactive parathyroid glands in a patient with renal hyperparathyroidism.

Authors:  Matti Raitza; Aziz A N Alshalali; Andor W J M Glaudemans; Rijk O B Gans; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-28       Impact factor: 9.236

4.  The EANM practice guidelines for parathyroid imaging.

Authors:  Petra Petranović Ovčariček; Luca Giovanella; Ignasi Carrió Gasset; Elif Hindié; Martin W Huellner; Markus Luster; Arnoldo Piccardo; Theresia Weber; Jean-Noël Talbot; Frederik Anton Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-10       Impact factor: 9.236

5.  99mTc-Sestamibi/123I Subtraction SPECT/CT in Parathyroid Scintigraphy: Is Additional Pinhole Imaging Useful?

Authors:  Virpi Tunninen; Pekka Varjo; Tomi Kauppinen; Anu Holm; Hannu Eskola; Marko Seppänen
Journal:  Int J Mol Imaging       Date:  2017-10-18

6.  Intraoperative Parathyroid Localization with Near-Infrared Fluorescence Imaging Using Indocyanine Green during Total Parathyroidectomy for Secondary Hyperparathyroidism.

Authors:  Le Cui; Yang Gao; Heping Yu; Min Li; Birong Wang; Tao Zhou; Qinggang Hu
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

7.  Absent 99mTc-MIBI Uptake in the Thyroid Gland during Early Phase of Parathyroid Scintigraphy in Patients with Primary and Secondary Hyperparathyroidism.

Authors:  Anamarija Jovanovska; Bojana Stoilovska; Magdalena Mileva; Daniela Miladinova; Venjamin Majstorov; Ana Ugrinska
Journal:  Open Access Maced J Med Sci       Date:  2018-05-10

8.  Is dual-phase SPECT/CT with 99mTc-sestamibi better than single-phase SPECT/CT for lesion localization in patients with hyperparathyroidism?

Authors:  Suk Hyun Lee; Eonwoo Shin; Sejin Ha; Jungsu S Oh; Dong Eun Song; Jin-Sook Ryu
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

9.  Unusual recurrent renal secondary hyperparathyroidism caused by hyperplastic autograft with supernumerary parathyroid adenoma: A case report.

Authors:  Jun Zhang; Meng-Jie Dong; Jun Yang; Dan Tian
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 10.  Is there a consensus between clinical practice guidelines for conventional and molecular nuclear medicine studies in parathyroid pathology?

Authors:  Marylin Acuña Hernandez; Liset Sanchez Orduz; Uvi Cancino Ramos; Paola Vallejo Armenta; Leonardo Cadavid Blanco
Journal:  Ann Nucl Med       Date:  2021-07-24       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.